Patrick Phillips, PhD, MS, MA

Associate Professor in Res

Pulmonary, Critical Care, Allergy and Sleep Medicine

As part of the UCSF Center for Tuberculosis, I am Associate Professor in Residence in the Division of Pulmonary and Critical Care Medicine with a secondary appointment in the Department of Epidemiology and Biostatistics. Prior to 2017 I was senior statistician at the MRC Clinical Trials Unit at UCL in London.

The objective of my research is to design, implement, and optimize clinical trials for new treatments for tuberculosis in order to deliver safer and more efficacious regimens for patients. I lead the Trial Design and Statistics core of the PanACEA consortium evaluating novel regimens for the treatment of TB, am consultant statistician for the US CDC-funded TB Trials Consortium (TBTC), and a member of the ACTG TB Transformative Science Steering Group. I have worked on late-phase clinical trials in tuberculosis for more than fifteen years, most recently as trial statistician in the STREAM Stage 1 and the TBTC/ACTG S31/A5349 phase III trials and vice-chair of ACTG A5414 SPECTR-TB. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs. I am an associate editor for the journal BMC Trials.

Education
PDip, 2010 - Postgraduate Diploma of the LSHTM by research in Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London
PhD, 2009 - Medical Statistics, London School of Hygiene and Tropical Medicine, University of London
MA, 2007 - Mathematics, Clare College, University of Cambridge
MSc, 2005 - Biometry, University of Reading
BA Hons, 2003 - Mathematics, Clare College, University of Cambridge
Websites
Publications

  1. Weir IR, Dufault SM, Phillips PPJ. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial. Trials 2024. PMID: 38468320


  2. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS medicine 2024. PMID: 38377166


  3. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly J, Worodria W, Cattamanchi A. New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 38306491


  4. Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB Network. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. The Lancet. Global health 2024. PMID: 38245113


  5. Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW. Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 37623745


  6. MacLean EL, Zimmer AJ, Boon SD, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM. Tuberculosis treatment monitoring tests during routine practice: study design guidance. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024. PMID: 38182047


  7. Dufault SM, Crook AM, Rolfe K, Phillips PPJ. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies. Statistics in medicine 2023. PMID: 38038137


  8. du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. Standards for clinical trials for treating TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023. PMID: 38042969


  9. Weir IR, Dufault SM, Phillips PP. Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial. Research square 2023. PMID: 37986887


  10. Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ. Treatment-shortening regimens for tuberculosis: updates and future priorities. Breathe (Sheffield, England) 2023. PMID: 37830101


  11. Stemkens R, Jager V, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE, PanACEA consortium. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrobial agents and chemotherapy 2023. PMID: 37768317


  12. Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci Trials 2023. PMID: 37280643


  13. Rehal S, Cro S, Phillips PP, Fielding K, Carpenter JR. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study. Clinical trials (London, England) 2023. PMID: 37277978


  14. Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P, AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. American journal of respiratory and critical care medicine 2023. PMID: 36790881


  15. Mpagama SG, Mvungi HC, Mbelele PM, Semvua HH, Liyoyo AA, de Guex KP, Sloan D, Kibiki GS, Boeree M, Phillips PPJ, Heysell SK. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania. Pilot and Feasibility Studies 2023. PMID: 37005695


  16. Koele SE, Phillips PPJ, Upton CM, van Ingen J, Simonsson USH, Diacon AH, Aarnoutse RE, Svensson EM. Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects. International journal of antimicrobial agents 2023. PMID: 36893811


  17. Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S, Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022. PMID: 36041016


  18. Ntinginya NE, Bakuli A, Mapamba D, Sabiiti W, Kibiki G, Minja LT, Kuchaka D, Reither K, Phillips PPJ, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N. TB-Molecular Bacterial Load Assay reveals early delayed bacterial killing in relapse patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022. PMID: 35717643


  19. Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3HP. AIDS (London, England) 2023. PMID: 36779500


  20. Phillips PPJ, Stout JE. To Err Is Human, to Forgive Is Pharmacodynamic. American journal of respiratory and critical care medicine 2023. PMID: 36165624


  21. Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM. A comparison of clinical development pathways to advance tuberculosis regimen development. BMC infectious diseases 2022. PMID: 36494644


  22. Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips P, Bryant K, Scott N, Vernon A, Kurbatova E, Chaisson RE, Dorman S, Nahid P, Swindells S, Dooley KE, Fletcher CV, AIDS Clinical Trials Group & Tuberculosis Trials Consortium. Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine. TO REMOVE 2021. PMID: 34918028


  23. Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022. PMID: 35996282


  24. Pham TM, Tweed CD, Carpenter JR, Kahan BC, Nunn AJ, Crook AM, Esmail H, Goodall R, Phillips PP, White IR. Rethinking intercurrent events in defining estimands for tuberculosis trials. Clinical trials (London, England) 2022. PMID: 35850542


  25. Semitala FC, Chaisson LH, Dowdy DW, Armstrong DT, Opira B, Aman K, Kamya M, Phillips PPJ, Yoon C. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. TO REMOVE 2022. PMID: 35550621


  26. Phillips PPJ, Kurbatova EV, Dorman SE. Four-Month Rifapentine Regimens for Tuberculosis. Reply. TO REMOVE 2022. PMID: 35294823


  27. Kritski A, Oliveira MM, Almeida IN, Ramalho D, Andrade MKN, Carvalho M, Miranda PFC, Dalcolmo MP, Braga JU, Brígido T, Mesquita E, Dias C, Gambirasio A, Souza Filho JB, Detjen A, Phillips PPJ, Langley I, Fujiwara P, Squire SB. Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial. Revista da Sociedade Brasileira de Medicina Tropical 2022. PMID: 35239898


  28. Dide-Agossou C, Rossmassler K, Reid J, Purohit J, Savic RM, Nahid P, Phillips PPJ, Moore CM, Walter ND. MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays. TO REMOVE 2022. PMID: 35192991


  29. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. TO REMOVE 2021. PMID: 34914696


  30. Imperial MZ, Phillips PPJ, Nahid P, Savic RM. Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. American journal of respiratory and critical care medicine 2021. PMID: 34346856


  31. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. TO REMOVE 2021. PMID: 34563240


  32. Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials 2021. PMID: 34344435


  33. Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE, Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculo. Optimising pyrazinamide for the treatment of tuberculosis. The European respiratory journal 2021. PMID: 33542052


  34. Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ, PanACEA Consortium. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin. The European respiratory journal 2021. PMID: 33542056


  35. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group , Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England journal of medicine 2021. PMID: 33951360


  36. Mbelele PM, Mpolya EA, Sauli E, Mtafya B, Ntinginya NE, Addo KK, Kreppel K, Mfinanga S, Phillips PPJ, Gillespie SH, Heysell SK, Sabiiti W, Mpagama SG. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania. Journal of clinical microbiology 2021. PMID: 33536294


  37. Eliseev, P. I.; Maryandyshev, A. O.; Detjen, A.; Dacombe, R.; Squire, S. B.; Phillips, P.. The use of molecular genetic diagnostic tests to improve MDR TB treatment outcomes in Arkhangelsk Region TO REMOVE 2021. PMID:


  38. Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, Conradie F, Chiang CY, Rusen ID, Nunn AJ. Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. BMC medicine 2020. PMID: 33143704


  39. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation science : IS 2020. PMID: 32787925


  40. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection. American journal of respiratory and critical care medicine 2020. PMID: 32282235


  41. Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, Oravcova K, Honeyborne I, Evangelopoulos D, McHugh TD, Khosa C, Rachow A, Heinrich N, Kampira E, Davies G, Bhatt N, Ntinginya EN, Viegas S, Jani I, Kamdolozi M, Mdolo A, Khonga M, Boeree MJ, Phillips PPJ, Sloan D, Hoelscher M, Kibiki G, Gillespie SH. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay. Thorax 2020. PMID: 32354738


  42. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. American journal of respiratory and critical care medicine 2019. PMID: 31711306


  43. Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, Tomeny EM, Nunn A, Phillips PP, Rusen ID, Squire SB. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Bulletin of the World Health Organization 2020. PMID: 32514196


  44. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary clinical trials 2020. PMID: 31981713


  45. Brookfield CR, Phillips PPJ, Shorten RJ. Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trial. BMJ (Clinical research ed.) 2019. PMID: 31852676


  46. Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ, Palchaudhuri P, Phillips PPJ, Schmok E, Taylor L, Abubakar I, Baker LV, Barrett JC, Burgess H, Cosgrove C, Dunleavy A, Francis M, Gupta U, Hamid S, Haselden BM, Holden E, Kahr V, Lynn W, Perrin FM, Rahman A, Soobratty MR. Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance. The European respiratory journal 2019. PMID: 31371444


  47. Morris TP, Jarvis CI, Cragg W, Phillips PPJ, Choodari-Oskooei B, Sydes MR. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate. BMJ open 2019. PMID: 31575572


  48. Nunn AJ, Phillips PPJ. A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply. The New England journal of medicine 2019. PMID: 31509688


  49. Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. BMC pulmonary medicine 2019. PMID: 31412895


  50. Abubakar I, Meredith S, Nunn AJ, Phillips PPJ, Rusen ID. STREAM: a pragmatic and explanatory trial for MDR-TB treatment. The Lancet. Infectious diseases 2019. PMID: 31122769


  51. Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P. Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics (Basel, Switzerland) 2019. PMID: 31151255


  52. Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM, PanACEA-MAMS-TB-01 Team. Protein binding of rifampicin is not saturated when using high-dose rifampicin. TO REMOVE 2019. PMID: 30597025


  53. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS medicine 2019. PMID: 30901331


  54. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine 2019. PMID: 30865791


  55. Bogdanova EN, Mariandyshev AO, Balantcev GA, Eliseev PI, Nikishova EI, Gaida AI, Enarson D, Detjen A, Dacombe R, Phillips PPJ, Squire SB, Gospodarevskaya E. Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation. PloS one 2019. PMID: 30695043


  56. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature medicine 2019. PMID: 30429542


  57. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature medicine 2018. PMID: 30397355


  58. Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrobial agents and chemotherapy 2018. PMID: 30012767


  59. Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC infectious diseases 2018. PMID: 29996783


  60. Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 29917079


  61. Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clinical trials (London, England) 2018. PMID: 29871495


  62. Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC medicine 2018. PMID: 29779492


  63. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. The Lancet. Respiratory medicine 2018. PMID: 29595509


  64. Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC medicine 2018. PMID: 29592805


  65. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials 2017. PMID: 29178937


  66. Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC medicine 2017. PMID: 29169355


  67. Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC medicine 2017. PMID: 29073910


  68. Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrobial agents and chemotherapy 2017. PMID: 28827417


  69. Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ. Testing many treatments within a single protocol over 10?years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical trials (London, England) 2017. PMID: 28830236


  70. Ramalho DMP, Miranda PFC, Andrade MK, Brígido T, Dalcolmo MP, Mesquita E, Dias CF, Gambirasio AN, Ueleres Braga J, Detjen A, Phillips PPJ, Langley I, Fujiwara PI, Squire SB, Oliveira MM, Kritski AL. Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil. BMC infectious diseases 2017. PMID: 28810911


  71. Phillips PPJ. Setting Tuberculosis Regimen Development on a Firm Foundation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017. PMID: 28402531


  72. Witney AA, Bateson AL, Jindani A, Phillips PP, Coleman D, Stoker NG, Butcher PD, McHugh TD. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC medicine 2017. PMID: 28351427


  73. Phillips PPJ. Methodological considerations in clinical trials for new MDR-TB treatment regimens. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016. PMID: 28240565


  74. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases 2016. PMID: 28100438


  75. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). International journal of geriatric psychiatry 2016. PMID: 27739182


  76. Rehal S, Morris TP, Fielding K, Carpenter JR, Phillips PP. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ open 2016. PMID: 27855102


  77. Bratton DJ, Parmar MK, Phillips PP, Choodari-Oskooei B. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. Trials 2016. PMID: 27369182


  78. Berry C, Yates TA, Seddon JA, Phillips PP, du Cros P. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. The European respiratory journal 2016. PMID: 27132271


  79. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, Ornstein T, Detjen A, Dacombe R, Gospodarevskaya E, Phillips PP, Mann G, Squire SB, Mariandyshev A. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PloS one 2016. PMID: 27055269


  80. Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC medicine 2016. PMID: 27004726


  81. Phillips PP, Fletcher HA, Abubakar I, Lipman MC, McHugh TD. World TB Day 2016: an interview with leading experts in tuberculosis research. BMC medicine 2016. PMID: 27007648


  82. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016. PMID: 27046707


  83. Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC medicine 2016. PMID: 26905218


  84. Phillips PP, Mendel CM, Burger DA, Crook AM, Crook A, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC medicine 2016. PMID: 26847437


  85. Dooley KE, Phillips PP, Nahid P, Hoelscher M. Challenges in the clinical assessment of novel tuberculosis drugs. Advanced drug delivery reviews 2016. PMID: 26827911


  86. Phillips PPJ & Nunn AJ. Infectious Disease Epidemiology. Abubakar I, Stagg HR, Cohen T, Rodrigues LC (Eds.) Clinical Trials 2016. PMID:


  87. Phillips PP, Morris TP, Walker AS. DOOR/RADAR: A Gateway Into the Unknown? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015. PMID: 26658302


  88. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet. Neurology 2015. PMID: 26515660


  89. Nunn AJ, Phillips PP, Abubakar I. Reducing relapse in tuberculosis treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015. PMID: 26459549


  90. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. A Step toward an Optimized Rifampin Dose Completed. American journal of respiratory and critical care medicine 2015. PMID: 26278799


  91. Bratton DJ, Choodari-Oskooei B, Phillips PP, Sydes MR, Parmar MK. Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd. Statistics in medicine 2015. PMID: 26147569


  92. Davies GR, Phillips PP, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015. PMID: 25946350


  93. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. American journal of respiratory and critical care medicine 2015. PMID: 25654354


  94. Phillips PP, Lipman MC. Safe and effective treatment for patients with isoniazid drug resistance. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015. PMID: 25860010


  95. Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. TO REMOVE 2015. PMID: 25651257


  96. Gillespie SH, Mendel CM. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine 2015. PMID: 25651256


  97. Sellier PO, Clevenbergh P, Bergmann JF. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. TO REMOVE 2015. PMID: 25651258


  98. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. The Journal of antimicrobial chemotherapy 2015. PMID: 25630641


  99. Nimmo C, Lipman M, Phillips PP, McHugh T, Nunn A, Abubakar I. Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. The Lancet. Infectious diseases 2015. PMID: 25749057


  100. Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH. The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. The Journal of antimicrobial chemotherapy 2014. PMID: 25344806


  101. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine 2014. PMID: 25337749


  102. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014. PMID: 25199531


  103. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine 2014. PMID: 25196020


  104. Turkova A, Seddon JA, Nunn AJ, Gibb DM, Phillips PP. Short intensified treatment in children with drug-susceptible tuberculous meningitis. The Pediatric infectious disease journal 2014. PMID: 25361029


  105. Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N. The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. Journal of clinical microbiology 2014. PMID: 24871215


  106. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. The Lancet. Infectious diseases 2014. PMID: 24670627


  107. Bratton DJ, Phillips PP, Parmar MK. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC medical research methodology 2013. PMID: 24229079


  108. Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bulletin of the World Health Organization 2013. PMID: 24391302


  109. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. The Lancet. Respiratory medicine 2013. PMID: 24429244


  110. Nunn AJ, Phillips PP. An analysis with serious flaws. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013. PMID: 23811419


  111. Phillips PP, Nunn AJ, Paton NI. Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013. PMID: 23676166


  112. Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PloS one 2013. PMID: 23667677


  113. Nunn A, Phillips PP, Abubakar I. Treatment of pulmonary tuberculosis. Current opinion in pulmonary medicine 2013. PMID: 23528955


  114. Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials 2013. PMID: 23536969


  115. Phillips PP, Bratton DJ, Nunn AJ, Hoelscher M. Reply to Dodd and Proschan. The Journal of infectious diseases 2012. PMID: 23175768


  116. Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn AJ. When inferiority meets non-inferiority: implications for interim analyses. Clinical trials (London, England) 2012. PMID: 22796636


  117. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. The Journal of infectious diseases 2012. PMID: 22448027


  118. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. The New England journal of medicine 2012. PMID: 22397651


  119. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. American journal of respiratory and critical care medicine 2011. PMID: 21737585


  120. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. Journal of clinical microbiology 2011. PMID: 21900522


  121. Perrin FM, Woodward N, Phillips PP, McHugh TD, Nunn AJ, Lipman MC, Gillespie SH. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010. PMID: 21144246


  122. Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International journal of geriatric psychiatry 2010. PMID: 20848576


  123. Dhillon J, Andries K, Phillips PP, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinburgh, Scotland) 2010. PMID: 20732832


  124. Phillips PP, Nunn AJ. Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. Future medicinal chemistry 2010. PMID: 21426018


  125. Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrobial agents and chemotherapy 2010. PMID: 20585110


  126. Phillips PP, Davies GR, Mitchison DA. Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet. Infectious diseases 2010. PMID: 20113973


  127. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010. PMID: 20074418


  128. Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials 2009. PMID: 19630974


  129. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinburgh, Scotland) 2008. PMID: 18762156


  130. Davies GR, Phillips PP, Nunn AJ. Biomarkers and surrogate end points in clinical trials of tuberculosis treatment. The Journal of infectious diseases 2007. PMID: 17624855


  131. A. Holdcroft, C. Dore, P. Phillips, M. Maze and M. Hanna. Cannabis in postoperative pain: a pharmacokinetic study TO REMOVE 2004. PMID: